Research analysts at Citigroup Inc. initiated coverage on shares of CRISPR Therapeutics AG Common Shares (NASDAQ:CRSP) in a research report issued on Tuesday. The brokerage set a “neutral” rating and a $19.00 price target on the stock. Citigroup Inc.’s price target suggests a potential downside of 11.96% from the stock’s previous close.

Other equities research analysts have also issued reports about the company. Guggenheim started coverage on CRISPR Therapeutics AG Common Shares in a research report on Monday. They set a “buy” rating and a $30.00 price target on the stock. Piper Jaffray Cos. started coverage on CRISPR Therapeutics AG Common Shares in a research report on Monday. They set an “overweight” rating and a $21.00 price target on the stock. Finally, Barclays PLC started coverage on CRISPR Therapeutics AG Common Shares in a research report on Monday. They set an “overweight” rating and a $22.00 price target on the stock.

Shares of CRISPR Therapeutics AG Common Shares (NASDAQ:CRSP) opened at 21.58 on Tuesday. The firm’s market cap is $113.55 million. The firm has a 50-day moving average price of $15.86 and a 200-day moving average price of $15.86. CRISPR Therapeutics AG Common Shares has a 12-month low of $13.75 and a 12-month high of $18.88.

In related news, Director Simeon George acquired 66,500 shares of the stock in a transaction that occurred on Monday, October 24th. The stock was purchased at an average cost of $14.00 per share, for a total transaction of $931,000.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Corp /De/ Celgene acquired 800,150 shares of the stock in a transaction that occurred on Monday, October 24th. The shares were bought at an average price of $14.00 per share, with a total value of $11,202,100.00. The disclosure for this purchase can be found here.

5 Day Chart for NASDAQ:CRSP

Receive News & Stock Ratings for CRISPR Therapeutics AG Common Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics AG Common Shares and related stocks with our FREE daily email newsletter.